Related Experiment Videos
From microarray to bedside: targeting NF-kappaB for therapy of lymphomas
Arnold B Rabson1, David Weissmann
1Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey, New Brunswick, NJ, USA. rabson@cabm.rutgers.edu
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A regulatory TRIF/IL-1R1 axis controls T-dependent IgA production in the intestines.
bioRxiv : the preprint server for biology·2026
ICAM-1 identifies preadipocytes and restricts white adipogenesis by adhering immune cells.
Cell death and differentiation·2025
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
DNMT3B plays antagonistic roles with SMARCB1 and is a targetable vulnerability in rhabdoid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
FDA Approval Summary: Retifanlimab for the treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy.
The Journal of experimental medicine·2026